Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions

Inclusion Criteria: * 18 years of age or older * Eligible for percutaneous coronary intervention and coronary artery bypass graft surgery. * Diagnosis of stable or unstable angina or silent ischemia * Left ventricular ejection fraction \>30% * The subject requires treatment of a single de novo lesion in a native coronary artery. * Lesion to be treated is less than or equal to 28 mm in length in a vessel that is 2.5-3.5mm diameter. * The target lesion diameter stenosis is \>50% and \<100% by visual estimate. * The target lesion is a minimum of 10 mm distance from any previously treated segment of the target vessel. * The subject understands the study requirements, is willing to comply with all study procedures and has provided written informed consent. Exclusion Criteria: * The subject has undergone coronary revascularization to any vessel within 30 days. * The subject has undergone target vessel revascularization within 6 months. * Treatment of more than one qualifying lesion is required at the time of enrollment, or is planned within 30 days following enrollment. * The subject has known sensitivity to sirolimus, paclitaxel, the polymeric matrices, stainless steel or cobalt chromium. * There is planned treatment of the target lesion with any device other than the pre-dilatation balloon angioplasty catheter. * The subject had a myocardial infarction within 72 hours, or presents with CK elevation \> 2 times upper limit normal associated with elevated CK-MB. * The subject is in cardiogenic shock. * The subject had a cerebrovascular accident within the past 6 months. * The subject has acute or chronic renal dysfunction (defined as creatinine \>2.0 mg/dl). * The subject has a contraindication to aspirin or clopidogrel. * The subject has thrombocytopenia (platelet count \< 100,000/mm3. * The subject has had active gastrointestinal bleeding within the past 3 months. * The subject has a known bleeding or hypercoagulable disorder. * The subject has had prior anaphylactoid reaction to contrast agents or has contrast sensitivity that cannot be controlled with pre-medication. * The subject is currently taking immunosuppressant therapy. * The subject is currently, or has been treated wtih either Rapamune or paclitaxel within 12 months of the procedure. * The subject is a female with a positive pregnancy test or is lactating. * The subject has an active infection. * The subject has co-morbidities that could interfere wtih completion of study procedures, or life expectancy less than 24 months. * The subject is participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study. Angiographic Exclusion Criteria * Left main disease \>50% diameter stenosis. * The target lesion is ostial. * The target lesion or target vessel are severely calcified. * The target lesion involves a bifurcation with diseased branch vessel greater than or equal to 2.0 mm that would require intervention or protection. * The target lesion has TIMI o or TIMI I flow. * Angiographic evidence of thrombus. * The target vessel has had prior stent placement. * The patient has had prior coronary brachytherapy. * There is angiographic restenosis of any previously treated segment of the target vessel, or atherosclerotic area wtih \>50% diameter stenosis outside of the target lesion. * The subject has undergone prior CABG.